Home › Research › Tau biomarkers
Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies
Iqbal K, Grundke-Iqbal I.. Current drug targets, 2004-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Neurofibrillary degeneration (ND) is both a pivotal and a primary lesion of Alzheimer disease (AD) and related tauopathies. To date in all known tauopathics including AD, the neurofibrillary changes, whether of paired helical filaments (PHF), twisted ribbons or straight filaments (SF) are made up of abnormally hyperphosphorylated tau, and the number of these lesions directly correlates to the degree of dementia in the affected individuals. Unlike normal tau which promotes assembly and maintains structure of microtubules, the abnormal tau not only lacks these functions but also sequesters normal tau, MAPI and MAP2, and causes disassembly of microtubules.
What this study adds
Evidence grade: Low
This is a narrative review. This paper reviews the role of abnormally phosphorylated tau and neurofibrillary degeneration in Alzheimer's disease and related tauopathies. It discusses the idea of blocking this process as a possible approach, but no treatment is tested here.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Iqbal, K., & Grundke-Iqbal, I. (2004). Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. Current drug targets. https://doi.org/10.2174/1389450043345254
Vancouver
Iqbal K, Grundke-Iqbal I. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. Current drug targets. 2004. doi:10.2174/1389450043345254. PMID: 15270196.
BibTeX
@article{iqbal2004-15270196,
author = {Iqbal, K. and Grundke-Iqbal, I.},
title = {{Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies}},
journal = {Current drug targets},
year = {2004},
doi = {10.2174/1389450043345254},
pmid = {15270196},
url = {https://doi.org/10.2174/1389450043345254}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- To date in all known tauopathics including AD, the neurofibrillary changes, whether of paired helical filaments (PHF), twisted ribbons or straight filaments (SF) are made up of abnormally hyperphosphorylated tau, and the number of these lesions directly correlates to the degree of dementia in the affected individuals.
- Unlike normal tau which promotes assembly and maintains structure of microtubules, the abnormal tau not only lacks these functions but also sequesters normal tau, MAPI and MAP2, and causes disassembly of microtubules.
- This toxic behavior of the abnormal tau is solely due to its hyperphosphorylation because dephosphorylation restores it into a normal-like protein.
- The abnormal hyperphosphorylation also promotes the self-assembly of tau into PHF/SF.
Why it matters
This paper reviews the role of abnormally phosphorylated tau and neurofibrillary degeneration in Alzheimer's disease and related tauopathies. It discusses the idea of blocking this process as a possible approach, but no treatment is tested here.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 34 of the 97 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current drug targets) |
| Journal's citation record | 1 / 4 | Current Drug Targets: journal h-index 139 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2004 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 35 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 24 year(s) since 2004 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Inge Grundke‐Iqbal: h-index 103 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15270196) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 97 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.